200 related articles for article (PubMed ID: 34063325)
1. NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.
Wu KJ; Li SH; Liao JB; Chiou CC; Wu CS; Chen CC
Biology (Basel); 2021 May; 10(5):. PubMed ID: 34063325
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.
Tang M; Gu XZ; Wu PC; Yang XT
J Inflamm Res; 2022; 15():2775-2787. PubMed ID: 35518839
[TBL] [Abstract][Full Text] [Related]
3. Primary intraosseous Rosai-Dorfman disease: An analysis of clinicopathologic characteristics, molecular genetics, and prognostic features.
Weng X; Yang Y; Zhang M; Cai C; Sun Y; Wu X; Zhang R; Gui H; Li W; Xu Q; Liu X
Front Oncol; 2022; 12():950114. PubMed ID: 36185213
[TBL] [Abstract][Full Text] [Related]
4. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Shanmugam V; Margolskee E; Kluk M; Giorgadze T; Orazi A
Head Neck Pathol; 2016 Sep; 10(3):394-9. PubMed ID: 26922062
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous Rosai-Dorfman disease with lack of BRAF-V600, KRAS or NRAS mutations: A reactive or neoplastic disorder?].
Machado I; Alcacer Fernández-Coronado J; Requena C; Través V; Latorre Martínez N; Ortega J; Requena L; Alcacer García J
Rev Esp Patol; 2022; 55(1):52-56. PubMed ID: 34980442
[TBL] [Abstract][Full Text] [Related]
6. Rosai-Dorfman Disease between Proliferation and Neoplasia.
Elbaz Younes I; Sokol L; Zhang L
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358690
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation.
Garces S; Medeiros LJ; Marques-Piubelli ML; Coelho Siqueira SA; Miranda RN; Cuglievan B; Sriganeshan V; Medina AM; Garces JC; Saluja K; Bhattacharjee MB; Khoury JD; Li S; Xu J; Jelloul FZ; Thakral B; Cameron Yin C
Hum Pathol; 2022 Mar; 121():36-45. PubMed ID: 34995673
[TBL] [Abstract][Full Text] [Related]
8. Atypical
Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
[TBL] [Abstract][Full Text] [Related]
9. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract][Full Text] [Related]
10. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
11. Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.
Akram AM; Chaudhary A; Kausar H; Althobaiti F; Abbas AS; Hussain Z; Fatima N; Zafar E; Asif W; Afzal U; Yousaf Z; Zafar A; Harakeh SM; Qamer S
Saudi J Biol Sci; 2021 Jul; 28(7):3735-3740. PubMed ID: 34220225
[TBL] [Abstract][Full Text] [Related]
12. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
13. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Ates O; Yalcin S
Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
[TBL] [Abstract][Full Text] [Related]
14. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.
Rutkowski P; Gos A; Jurkowska M; Switaj T; Dziewirski W; Zdzienicki M; Ptaszyński K; Michej W; Tysarowski A; Siedlecki JA
Oncol Lett; 2014 Jul; 8(1):47-54. PubMed ID: 24959217
[TBL] [Abstract][Full Text] [Related]
16. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
17. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
18. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
19. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
Abeykoon JP; Rech KL; Young JR; Ravindran A; Ruan GJ; Dasari S; Morlote DM; King RL; Rummage C; Zanwar S; Acosta-Medina AM; Tobin WO; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Witzig TE; Goyal G; Go RS;
JAMA Oncol; 2022 Dec; 8(12):1816-1820. PubMed ID: 36201194
[TBL] [Abstract][Full Text] [Related]
20. Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.
Pereira TDSF; de Amorim LSD; Pereira NB; Vitório JG; Duarte-Andrade FF; Guimarães LM; Diniz MG; Gomes CC; Gomez RS
J Oral Pathol Med; 2019 Nov; 48(10):906-910. PubMed ID: 31310691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
